Gut & MicrobiomePress Release

Antibodies blocking IL-10 explain a 30-year inflammatory bowel disease genetic mystery

Oxford-led researchers found that about 3.5% of IBD patients carry antibodies that disable IL-10, a key anti-inflammatory signal, and linked them to a high-risk gene variant.

Tuesday, November 17, 2026 0 views
Published in ScienceDaily Gut
Article visualization: Antibodies blocking IL-10 explain a 30-year inflammatory bowel disease genetic mystery

Summary

Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, may be several distinct conditions rather than one. In a New England Journal of Medicine study of more than 4,900 people with IBD, researchers from Oxford, Newcastle and Cambridge found that about 3.5% of patients carry antibodies that neutralize interleukin-10 (IL-10), a protein that keeps inflammation in check. These antibodies appeared in both Crohn's disease and ulcerative colitis but not in healthy people. The antibodies were strongly tied to a genetic variant, HLA-DRB1*01:03, first linked to severe IBD 30 years ago without a known mechanism. Carriers of the variant are much more likely to make the antibodies, which disable a built-in brake on immune activity. The team estimates 15,000 to 20,000 patients in the UK could be affected. The finding could allow more precise diagnosis and treatments matched to the underlying cause, though clinical testing is still needed.

Detailed Summary

Inflammatory bowel disease (IBD), made up of Crohn's disease and ulcerative colitis, affects about 500,000 people in the UK and millions worldwide. It often begins in adolescence or early adulthood and can mean a lifetime of immune-suppressing drugs, hospital visits and sometimes surgery. Many patients cycle through several therapies without lasting relief, so understanding why treatments fail for some people matters greatly for long-term health and quality of life.

In a study published in the New England Journal of Medicine, researchers from the University of Oxford, Newcastle University and Cambridge University Hospitals examined more than 4,900 people with IBD. They found that roughly 3.5% had elevated antibodies that neutralize interleukin-10 (IL-10), a messenger protein that helps the immune system prevent excessive inflammation. These antibodies appeared in both Crohn's disease and ulcerative colitis but were absent in healthy individuals.

The work also solved a decades-old genetic puzzle. Oxford scientists linked the variant HLA-DRB1*01:03 to a severe form of IBD 30 years ago, but the biology was unclear. Carriers of this variant are substantially more likely to develop IL-10-blocking antibodies, which explains how the gene contributes to severe intestinal inflammation. With the brake on inflammation disabled, the immune response can persist and become hard to control.

The findings suggest IBD is not one disease but several biologically distinct conditions. Based on UK prevalence, an estimated 15,000 to 20,000 patients may carry these antibodies. In principle, antibody testing could identify them and guide more targeted treatment, rather than the trial-and-error approach common today.

Several caveats apply. The antibodies explain only a small share of IBD cases, and the news report does not describe whether testing changes outcomes or which therapies would work best for these patients. Treatments aimed at this mechanism still need to be developed and tested in clinical trials, and patients should not change therapy based on this finding.

Key Findings

  • About 3.5% of 4,900+ IBD patients had antibodies neutralizing IL-10, a key anti-inflammatory protein.
  • The antibodies occurred in Crohn's disease and ulcerative colitis but not in healthy individuals.
  • HLA-DRB1*01:03, a severe-IBD risk variant found 30 years ago, strongly predicts these antibodies.
  • An estimated 15,000 to 20,000 UK patients may carry the harmful antibodies.
  • IBD appears to include biologically distinct subtypes, opening the door to cause-targeted diagnosis and treatment.

Methodology

This is a news report on a peer-reviewed study in the New England Journal of Medicine, a highly credible journal. The study analyzed samples from more than 4,900 people with IBD compared with healthy controls. The summary comes from a university press release, so details are limited.

Study Limitations

Only a small fraction of patients carry these antibodies, so most IBD cases remain unexplained by this mechanism. The article does not report whether the antibodies cause disease directly in all carriers or whether targeted treatments improve outcomes. Verify details such as assay methods and effect sizes in the original NEJM paper.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: